Introduction {#sec1}
============

Hemolysis and anemia may occur after heart valve replacement surgery as a result of turbulent flow pattern and erythrocyte destruction. They can be caused by imperfect design of old-generation prostheses, but currently the development of paravalvular leak (PVL) is more frequently the reason \[[@cit0001]\]. The incidence of clinically relevant PVL in patients with a surgical prosthetic valve is estimated at a few percent \[[@cit0002]--[@cit0004]\]. The PVL is considered significant if it causes heart failure (HF) symptoms and/or hemolytic anemia. In such patients surgical correction is associated with high mortality and also with a substantial recurrence rate \[[@cit0005]--[@cit0008]\]. Therefore transcatheter PVL closure (TPVLC) is a valid alternative. It was first reported by Hourihan *et al.* in 1992 \[[@cit0009]\]. Over the subsequent years its safety and feasibility were documented both in children \[[@cit0010]\] and adults \[[@cit0011]--[@cit0014]\]. Despite the lack of randomized trials, consistent data from case series and registries resulted in the TPVLC class IIa recommendation being granted by the American Heart Association/American College of Cardiology \[[@cit0015]\]. This was mainly based on proven effectiveness of TPVLC in reduction of HF symptoms.

The effects of TPVLC on hemolysis and anemia have not been systematically studied in prospective studies despite the clinical significance of this problem. Full exclusion of the PVL by an occluder has the potential to reduce the hemolytic anemia. On the other hand, some case reports have suggested that TPVLC may exacerbate the hemolysis. Our prospective single-center registry systematically evaluated the long-term outcomes of all patients with significant PVL related to surgical valve replacement (SVR) treated with TPVLC. In the current study we investigated the population of patients presenting with HF related to PVL and/or coexisting hemolytic anemia in order to evaluate the long-term effects of TPVLC on anemia recovery and to identify potential factors leading to postprocedural hemolysis.

Material and methods {#sec2}
====================

The current report on hemolysis is based on data from a prospective registry including all consecutive patients with PVL related to SVR referred to our institution for TPVLC. The aim of the study was to evaluate the outcomes of selected patients presenting with heart failure and/or significant hemolysis, and the following criteria were used to identify the target population: age \> 18 years, history of surgical aortic or mitral valve replacement (AVR, MVR) complicated by symptomatic (HF and/or hemolytic anemia) PVL in whom TPVLC was indicated. Exclusion criteria were as follows: anemia related to factors other than hemolysis (bleeding, cancer, chronic inflammation); presence of multiple PVLs with at least one deemed unsuitable for TPVLC (anatomy, size, location); indications for surgical repair (prosthetic valve instability, structural deterioration of prosthetic valve, need for coronary artery bypass grafting, active infective endocarditis) or unexplained elevation of inflammatory markers (WBC, CRP).

Data were collected during the index hospitalization (on admission and at discharge) and on an ambulatory basis after 1 and 6 months. Demographic, clinical and procedural data were prospectively recorded. Laboratory tests included hemoglobin (HGB) concentration, red blood cell count (RBCC) and lactate dehydrogenase (LDH) activity (values above 400 IU/l were considered a cut-off for hemolysis). If multistage TPVLC was necessary, the follow-up was 6 months after the final procedure. The TPVLC-related hemolysis was defined as a rise in LDH activity by at least 100 IU/l from the initial value in any of the follow-up samples. Periprocedural (within 24 h) and in-hospital MACCE (death/MI/stroke) were recorded. Bleeding events were classified according to VARC-2 criteria \[[@cit0016]\].

Transthoracic echocardiography (TTE) and transesophageal echocardiography with real-time three-dimensional imaging (RT 3D TEE) were performed with the Philips iE33 system. The following parameters were measured: cross-sectional area (CSA), minimum and maximum dimensions of the PVL channel with acquisition of the smallest volume containing the PVL channel in a zoom mode with color Doppler (CD) mapping in single-beat acquisition mode. Multi-planar reconstruction enabled positioning of the measurement plane exactly perpendicular to the PVL. For a sample RT-3D TEE image see [Figure 1 A](#f0001){ref-type="fig"}.

![**A** -- Multi-planar reconstruction of RT 3D TEE data set -- measurement of CSA (left panel) and minimum and maximum dimensions (right panel) of mitral PVL. **B** -- Assessment of the completeness of PVL sealing -- comparison of baseline (left panel) vs. postprocedural (right panel) CSA of PVL -- 75% reduction of aortic PVL CSA. **C** -- Visualization of residual regurgitant flow through the structure of the PLD occluder (dotted black line). **D** -- An example of a calcified PVL channel (dotted black line)](AMS-13-27718-g001){#f0001}

Accordingly we determined the type, size and a number of plugs needed for the most complete closure of a PVL. Amplatzer Vascular Plug (AVP) II or III devices were used to achieve at least a 150% oversizing of the occluders' middle modules' CSA in comparison to the PVL's CSA. To avoid potential instability of multiple occluders a maximum of 4 AVPs were implanted into a single PVL. For the Occlutech Paravalvular Leak Device (PLD) \[[@cit0017]\] the size was directly matched to the minimum and maximum dimensions of the PVL with no oversizing and used as a single device only. Intraprocedurally, RT 3D TEE was used to guide the procedure and to assess the completeness of PVL sealing ([Figure 1 B](#f0001){ref-type="fig"}), in particular to visualize residual regurgitant flow through the device ([Figure 1 C](#f0001){ref-type="fig"}). The TTE was repeated after 1 and 6 months to assess the stability of the occluders, function of the prosthetic valve and long-term hemodynamic effect of TPVLC. The RT 3D TEE was performed after 6 months to visualize any new regurgitation or residual PVL. During TPVLC the anatomy of PVL channel including the distribution of calcium deposits was also assessed angiographically at least in 2 orthogonal projections with maximum exposure parameters ([Figure 1 D](#f0001){ref-type="fig"}).

For aortic TPVLC a retrograde transfemoral access was uniformly used, while for mitral TPVLC either transseptal or transapical access was used.

The study was approved by the Ethics Committee of the Medical University of Silesia and supported by a STRATEGMED II grant (National Centre for Research and Development, STRATEGMED2/269488/7/NCBR/2015). All procedures were in accordance with the 1964 Declaration of Helsinki. All patients gave informed consent for TPVLC.

Statistical analysis {#sec2.1}
--------------------

Categorical variables were presented as numbers and percentage. Continuous variables were expressed as mean ± standard deviation (SD) or median and interquartile range (IQR). Differences between groups were compared using Student's or Welch's *t*-test depending on the equality of variances for normally distributed variables. The Mann-Whitney *U* test was used for non-normally distributed continuous variables. Normality was assessed by the Shapiro-Wilk test. Equality of variances was assessed using Levene's test. Categorical variables were compared by Fisher's exact test for 2 × 2 tables. For tables with more than two rows or columns Pearson's χ^2^ test was used. The Pearson correlation coefficient was calculated to measure the linear dependence between two normally distributed variables. For non-normally distributed variables Spearman's rank correlation coefficient was calculated to measure the monotonic trend. Multivariate models were fitted using backward stepwise regression with the Wald χ^2^ *p* \< 0.05 threshold stopping rule. Potential confounders (age and gender) were included in the models a priori.

Two-sided *p*-values \< 0.05 were considered statistically significant in all analyses. All calculations were done with JMP, version 9.0.0, SAS Institute Inc., Cary, NC, 1989-2007.

Results {#sec3}
=======

One hundred sixteen patients underwent TPVLC in our institution between 2010 Jan and 2015, and 79 of them were enrolled in this hemolysis registry. The inclusion and exclusion criteria were described in the methods section. From 116 patients 37 were excluded for the following reasons: bleeding episodes (mostly patients requiring anticoagulation and dual antiplatelet therapy, *n* = 19), presence of multiple PVL, with at least one unsuitable for TPVLC (*n* = 11), current anti-neoplastic therapy (*n* = 4), deficiency anemia (*n* = 3).

Preprocedural hemolysis was present in 50 patients. It was accompanied by severe anemia requiring transfusion in 9 patients. The majority of patients had a mechanical prosthetic valve.

Forty-three patients were treated due to mitral and 33 due to aortic PVL. The following surgical valves were implanted: aortic (ATS (ATS Medical), *n* = 11, SJM Regent (St Jude Medical), *n* = 8, Hancock Ultra (Medtronic), *n* = 7, St Jude Epic (St Jude Medical), *n* = 5, Cardiomedics (Sorin), *n* = 2) and mitral (ATS (ATS Medical), *n* = 14, Carpentier (Edwards Perimount (Edwards), *n* = 13, SJM (St Jude), *n* = 9, Hancock/Hancock II (Medtronic), *n* = 5, Sorin Bicarbon (Sorin), *n* = 5). The SVR procedures were done with routinely used techniques (AVR with decalcification and supra-annular position and MVR with single sutures and pledgets). Patients were referred from 5 cardiac surgery centers.

Further demographic and initial clinical data are presented in [Table I](#t0001){ref-type="table"}.

###### 

Baseline demographic and clinical data

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                                                                                    Result
  ---------------------------------------------------------------------------------------------------------------------------- ----------------------
  Number of patients                                                                                                           79

  Male, *n* (%)                                                                                                                39 (52)

  Age, mean ± SD \[years\]                                                                                                     63.7 ±11.6

  Chronic medications, *n* (%):                                                                                                

   VKA                                                                                                                         45 (57)

   DAPT                                                                                                                        7 (9)

   NOAC                                                                                                                        5 (6)

  LVEF, mean ± SD \[%\]                                                                                                        39 ±7.8

  Severe chronic kidney disease (GFR 15--29 ml/min/1.73 m^2^)/end-stage kidney disease (GFR \< 15 ml/min/1.73 m^2^), *n* (%)   5 (6)/none

  Diabetes, *n* (%)                                                                                                            23 (29)

  History of coronary revascularization, *n* (%)                                                                               29 (37)

  EuroSCORE II (logistic)                                                                                                      11.3 (5.6--17.6)

  Endocarditis before valve replacement, *n* (%)                                                                               8 (10)

  Number of previous target valve replacements:                                                                                

   1                                                                                                                           43

   2                                                                                                                           29

   3                                                                                                                           5

  Time from valve replacement to TPVLC \[months\]                                                                              24 (12--43.5)

  PVL at biological prosthesis, *n* (%)                                                                                        30 (38)

  PVL at mechanical prosthesis, *n* (%)                                                                                        49 (62)

  Coexistence of mitral and aortic mechanical prosthesis, *n* (%)                                                              25 (32)

  Hemodynamically important PVL, *n* (%)                                                                                       71 (90)

  Hemolysis parameters:                                                                                                        

   Baseline LDH \[IU/l\]                                                                                                       698.0 ±499.5\
                                                                                                                               617.0 (342.0--899.0)

   Hemoglobin \[g/dl\]                                                                                                         12.1 ±2.1\
                                                                                                                               11.7 (10.4--13.0)

   RBCC \[M/mm^3^\]                                                                                                            3.9 ±0.7\
                                                                                                                               3.9 (3.3--4.1)

   Need for transfusion/erythropoietin administration                                                                          9 (11%)/none

  Number of patients with LDH \> 400 IU/l                                                                                      50

  Number of patients with HGB \< 11 g/dl                                                                                       42
  ---------------------------------------------------------------------------------------------------------------------------------------------------

Procedural characteristics {#sec3.1}
--------------------------

Fifty-four patients underwent a single-stage TPVLC and 25 patients had a two-stage procedure. AVP II or III devices were used in 70 cases and PLD devices in 9 cases. All patients completed the 6-month follow-up. More procedural details are presented in [Table II](#t0002){ref-type="table"}.

###### 

Procedural characteristics

  Variable                             Result
  ------------------------------------ ----------------------------------------------------------------------------
  Mitral PVLs:                         
   Total number of patients            46
   Single PVL                          35
   Multiple PVL (2)                    11
   Total number of procedures          60 (incl. closure of 2 PVLs in the same patient during the same procedure)
   Multi-stage procedures              14
   Planned                             10 (multiple PVLs)
   After failed 1^st^ attempt          4 (switch to transapical access)
   Implanted occluders (per PVL):      
    1 × AVP II                         2
    2 × AVP II                         2
    1 × AVP III                        7
    2 × AVP III                        18
    3 × AVP III                        19
    4 × AVP III                        6
    1 × PLD                            6
   Number of transseptal procedures    49
   Number of transapical procedures:   11
    Planned access                     7
    After failed transseptal attempt   4
  Aortic PVLs:                         
   Total number of patients:           33
    Single PVL                         22
    Multiple PVL (2)                   9
    Multiple PVL (3)                   2
   Total number of procedures:         44
    Multi-stage procedures             11
    Planned                            11
    After failed 1^st^ attempt         0
  Implanted occluders (per PVL):       
    1 × AVP II                         2
    2 × AVP II                         1
    1 × AVP III                        5
    2 × AVP III                        22
    3 × AVP III                        11
    1 × PLD                            3

In-hospital major adverse cardiovascular and cerebrovascular event (MACCE) (non-disabling stroke presenting as aphasia that fully resolved) occurred in 1 patient. There was 1 case of life-threatening intrapleural bleeding after the transapical procedure that warranted transfusion of 3 RBCC units. No other major bleeding occurred. There were 4 cases of minor access site bleeding that resolved with conservative management.

During 6 months there were no late procedural complications (occluder dislocations, recurrence of significant PVL, surgical valve replacement). One patient required two hospitalizations and PRBC transfusion due to persistent hemolytic anemia associated with incomplete closure of the PVL. One patient with incomplete TPVLC on the mitral prosthetic valve required hospitalization at month 4 due to decompensated HF.

Factors influencing the preprocedural hemolysis {#sec3.2}
-----------------------------------------------

Patients were stratified according to the presence of significant baseline PVL-related hemolysis, and characteristics of both groups are shown in [Table III](#t0003){ref-type="table"}. Patients with significant preprocedural hemolysis more often presented with a calcified PVL channel as assessed by fluoroscopy. Mitral location of the PVL was also more frequent in this group as compared to patients without anemia.

###### 

Comparison of patients with and without significant hemolysis

  Parameter                                                  LDH1                   *P*-value               
  ---------------------------------------------------------- ---------------------- ----------------------- -----------
  Age \[years\]                                              66.0 (59.5--74.5)      63.0 (58.0--73.0)       0.1081
  LVEF \[%\]                                                 42.24 ±8.4             43.9 ±7.8               0.3085
  HGB \[g/dl\]                                               14.1 (13.3--15.2)      10.7 (10.1--11.7)       \< 0.0001
  RBCC \[M/mm^3^\]                                           4.5 (4.1--5.0)         3.7 (3.1--3.9)          \< 0.0001
  LDH \[IU/l\]                                               268.0 (186.8--343.0)   781.0 (662.0--1110.0)   \< 0.0001
  PVL related to biological/mechanical prosthesis, *n* (%)   10 (34.5)/19 (65.5)    20 (40.0)/30 (60.0)     0.8103
  PVL related to mitral/aortic prosthesis, *n* (%)           12 (41.4)/17 (58.6)    34 (68.0)/16 (32.0)     0.0326
  Both prostheses mechanical, *n* (%)                        8 (27.6)               17 (34.0)               0.6222
  PVL calcifications                                         4 (13.8)               32 (64.0)               \< 0.001

Influence of transcatheter paravalvular leak closure on hemolysis {#sec3.3}
-----------------------------------------------------------------

The TPVLC led to a significant reduction of the LDH activity already at discharge followed by a further decrease in long-term follow-up between months 1 and 6 ([Figure 2](#f0002){ref-type="fig"}). Consistently the RBCC and HGB levels gradually increased. Values of LDH activity, RBCC, and HGB concentration are presented in [Table IV](#t0004){ref-type="table"}.

###### 

Laboratory markers of hemolytic anemia for all patients

  Parameter          Baseline (1)           Discharge (2)                                           1 month (3)                                           6 months (4)
  ------------------ ---------------------- ------------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  HGB \[g/dl\]       11.7 (10.4--13.8)      11.4 (10.1--13.0)                                       12.9 (12.0--13.9)[\*](#tf4-1){ref-type="table-fn"}    13.4 (12.9--13.8)[\*](#tf4-1){ref-type="table-fn"}
  RBCC \[M/mm^3^\]   4.1 (3.9--4.5)         3.7 (3.3--4.1)                                          4.2 (3.9--4.5)                                        4.4 (4.2--4.7)[\*](#tf4-1){ref-type="table-fn"}
  LDH \[IU/l\]       617.0 (342.0--899.0)   388.0 (300.0--539.0)[\*](#tf4-1){ref-type="table-fn"}   412 (334.0--507.0)[\*](#tf4-1){ref-type="table-fn"}   397 (310.0--480.5)[\*](#tf4-1){ref-type="table-fn"}

p \< 0.05 for comparison with baseline values.

![Lactate dehydrogenase activity during 6-month follow-up in all patients](AMS-13-27718-g002){#f0002}

Only 1 patient, suffering from severe baseline hemolysis, with irregularly shaped and heavily calcified PVL with hemodynamically mild post-procedural residue, required PRBC transfusions after TPVLC.

There were 14 (19.7%) patients who fulfilled criteria of TPVLC-related hemolysis during the follow-up. LDH activities found in these subjects are presented in [Figure 3](#f0003){ref-type="fig"}. The HGB concentrations in the TPVLC-related hemolysis group and other patients are comparatively presented in [Table V](#t0005){ref-type="table"}. As shown, TPVLC-related hemolysis was related to a gradual decrease in HGB concentration, but the difference between the groups was statistically insignificant. Except for the patient mentioned above, it did not prove clinically relevant over the 6-month follow-up, either.

###### 

HGB concentrations \[g/dl\] in patients with and without TPVLC-related hemolysis

  ---------------------------------------------------------------------------------------------
  Time point   TPVLC-related hemolysis absent\   TPVLC-related hemolysis present\   *P*-value
               *N* = 65                          *N* = 14                           
  ------------ --------------------------------- ---------------------------------- -----------
  Baseline     11.9 ±2.1\                        12.1 ±2.05\                        0.1376
               11.5 (10.2--13.8)                 11.7 (10.4--13.8)                  

  Discharge    11.6 ±1.7\                        12.0 ±1.5\                         0.3372
               11.2 (10.1--13.0)                 12.1 (11.0--13.4)                  

  1 month      13.0 ±1.9\                        12.8 ±1.9\                         0.6728
               13.0 (12.1--13.9)                 12.7 (11.3--14.1)                  

  6 months     13.4 ±0.9\                        12.7 ±1.5\                         0.3097
               13.4 (13.0--13.9)                 13.3 (11.9--13.7)                  
  ---------------------------------------------------------------------------------------------

![Lactate dehydrogenase activity in patients with TPVLC-related hemolysis](AMS-13-27718-g003){#f0003}

To determine whether baseline LDH activity influenced its post-procedural value the correlation between consecutive samples (baseline/discharge/1 month/6 months) was sought individually for each patient. The results are presented in [Figure 4](#f0004){ref-type="fig"}. Remarkably, a positive correlation was found in each compared pair of samples -- greater magnitude of hemolysis prior to TPVLC predicted higher LDH activity in follow-up.

![Changes of LDH activity in pairs of samples](AMS-13-27718-g004){#f0004}

Relation between degree of PVL sealing and hemolysis {#sec3.4}
----------------------------------------------------

Efficacy of PVL sealing was assessed in 75 patients by comparison of residual CSA after deployment of plugs to its baseline value. Four patients were excluded from this analysis on the grounds of insufficient quality of post-procedural echocardiography images (acoustic shadowing by plugs).

Generally, degree of residual PVL (percentage of uncovered PVL CSA) correlated negatively with increase of RBCC (*r* = --0.24; *p* = 0.04) and positively with LDH activity (*r* = 0.28; *p* = 0.03) in 1-month follow-up.

Next, patients with complete sealing of the PVL (*n* = 30) were compared to those with any degree of the residual leak. There were higher average values of HGB concentration and RBCC in the first group, but statistical significance was only reached in the case of LDH activity at discharge: 367.1 ±183.6 vs. 474.7 ±185.0 IU/l (*p* = 0.0263), respectively.

Additionally, an attempt was made to identify a degree of PVL reduction which would ensure a beneficial effect on hemolysis. We found a decrease of PVL CSA by at least 90% to result in a more prominent increase of RBCC and HGB concentration. Though statistically insignificant, there was also a greater average LDH activity reduction at the same CSA reduction threshold ([Table VI](#t0006){ref-type="table"}).

###### 

Changes in HGB concentration, RBC and LDH activity with respect to degree of PVL CSA reduction

  ---------------------------------------------------------------------------------------------------------------
  Variable                                     Reduction of CSA \< 90%\   Reduction of CSA ≥ 90%\     *P*-value
                                               *N* = 16                   *N* = 59                    
  -------------------------------------------- -------------------------- --------------------------- -----------
  ΔHGB~discharge\ --\ 1\ month~ \[g/dl\]       0.7 ±1.1\                  1.3 ±1.0\                   0.0365
                                               0.7 (0.2--0.9)             1.2 (0.5--2.0)              

  ΔHGB~baseline\ --\ 6\ months~ \[g/dl\]       0.0 ±1.8                   1.6 ±1.6                    0.0020

  ΔRBCC~discharge\ --\ 1\ month~ \[M/mm^3^\]   0.2 ±0.3\                  0.5 ±0.3\                   0.0007
                                               0.1 (--0.1 -- 0.4)         0.5 (0.2--0.7)              

  ΔRBCC~baseline\ --\ 6\ months~ \[M/mm^3^\]   --0.1 ±0.7\                0.6 ±0.5\                   0.0003
                                               0.0 (--0.9 -- 0.4)         0.6 (0.2--0.9)              

  ΔLDH~discharge\ --\ 1\ month~ \[IU/l\]       48.9 ±260.5\               8.9 ±181.4\                 0.3512
                                               38.0 (36.8--108.0)         3.0 (--88.0 -- 73.0)        

  ΔLDH~baseline\ --\ 6\ months~ \[IU/l\]       --164.9 ±577.3\            --296.9 ±508.1\             0.2547
                                               --6.0 (--290.0 -- 117.0)   --173.0 (--487.0 -- 28.0)   
  ---------------------------------------------------------------------------------------------------------------

Finally, we used logistic analysis to identify risk factors for TPVLC-related hemolysis among the following: age, sex, site and type of prosthesis (biological/mechanical), presence of 2 prosthetic valves, left ventricular ejection fraction (LVEF), baseline values of laboratory markers (LDH activity, HGB concentration and RBCC), flow across the occluding device on TEE after deployment, and PVL CSA before and after the procedure. Contrary to baseline presentation, the TPVLC-related hemolysis occurrence rate was not affected by PVL location. The risk of this complication turned out to be related to initially present significant hemolysis (*p* = 0.0264) and identification of residual regurgitant flow across the structure of the occluder(s) by color flow mapping on TEE (*p* = 0.0007). The latter increased the risk by 5-fold at 1 month (95% CI: 1.3--26.4; *p* = 0.0331) and 4.6-fold at 6 months (95% CI: 1.1--24.7; *p* = 0.0374). Secondly, each additional CSA square millimeter of residual PVL (across uncovered parts of the channel) corresponded to 9.7-fold increase of post-procedural TPVLC-related hemolysis risk (95% CI: 1.5--100.7; *p* = 0.0151).

Discussion {#sec4}
==========

One of the fundamental studies on mechanisms of PVL-related hemolysis \[[@cit0018]\] introduced the concept of jet fragmentation on irregular walls of a paravalvular defect. The same phenomenon, probably occurring in the presence of a calcified (and then often irregularly shaped) PVL channel, could explain our findings that patients with significant preprocedural hemolysis more often presented with a calcified PVL channel as assessed by fluoroscopy.

Some previously published papers addressed the possibility of a bidirectional influence of TPVLC on hemolysis, occasionally also hinting at the significance of TPVLC completeness \[[@cit0019]--[@cit0024]\]. Ruiz *et al.* reported a reduction in the need for transfusion or erythropoietin administration from an initial 56% to 5% at follow-up \[[@cit0025]\]. In the largest hitherto published series of patients undergoing TPVLC (*n* = 136, the majority treated due to PVL-related HF) hemolytic anemia was post-procedurally present in 14 of 129 survivors, with only 1 case of hemolysis exacerbation \[[@cit0011]\]. The authors suggested enhancing TPVLC efficacy in their last 12 patients by the introduction of the multiplug technique, which was also commonly applied to our patients. In a study by Nijenhuis *et al.* \[[@cit0026]\] 17% of patients after transapical TPVLC still required PRBC transfusions even though some reduction of hemolysis markers was noted. The majority of these patients (53% for mitral and 86% for aortic location) were treated with single device implantation, predominantly AVP III. As no information on residual flow across the device was published, the explanation of the hemolysis mechanism is difficult. In another publication on TPVLC performed with AVP III devices Cruz-Gonzalez *et al.* reported a reduction in the need for periodic transfusions from 51.5% to 9.1% \[[@cit0027]\].

In 2015 a meta-analysis of 12 non-randomized studies on TPVLC showed that successful transcatheter reduction of PVL improved NYHA functional class or hemolytic anemia (*n* = 267, OR = 9.95; 95% CI: 2.10--66.73) \[[@cit0028]\]. Nevertheless, the evaluation of TPVLC influence on hemolysis alone was impossible because of wide credible intervals for the estimated effect (*n* = 35, OR = 2.22, 95% CI: 0.06--194).

In our study, a slight decrease in RBCC and HGB concentration was present immediately after TPVLC. Conceivably, this should be attributed to procedural blood loss as the LDH activity lowered promptly and both RBCC and HGB concentration gradually rose during the follow-up in all patients. Exacerbation of hemolysis after TPVLC, which occurred in some patients, resolved during the follow-up, most apparently in the first month. On the other hand, we observed that resolution of baseline hemolytic anemia is not to be expected unless a nearly total occlusion of PVL is achieved intraprocedurally. This is probably due to high velocity of any residual paravalvular flow, rendering clotting unlikely.

Interestingly, higher LDH activities at baseline were followed by higher values in follow-up in the same patients (even though reduced to some extent by TPVLC). This finding could be related to anatomical features of the PVL channel. We speculate that irregular and calcified PVL channels might not only exacerbate hemolysis initially but also continue their effect post-procedurally if left partially uncovered.

We only included patients in whom, based on imaging findings, closure of all PVLs seemed feasible. Consequently, we did not analyze data from patients who were denied TPVLC on grounds of unfavorable anatomy. In many cases, it meant the presence of multiple small PVL channels with sutures in between, which not only hampers TPVLC but also may itself cause significant hemolysis.

Imaging limitations are the next important factor. Echocardiography still lacks a gold standard method of PVL quantification. Quantification of PVL circumferential extent along with a number of traditional regurgitation indicators has been recommended. Still, PVL channel CSA measurement by 3D RT TEE, while enabling both optimal choice of occluding devices and monitoring of the procedure efficacy, seems particularly useful for TPVLC. Identification of sutures crossing the PVL channel, while important for preprocedural planning, may still be challenging with the currently achievable spatial resolution. Assessment of presence and extent of calcifications occupying areas considered as landing zones for occluders is another issue exposed to subjectivity both on echocardiography and fluoroscopy.

Another limitation is the study sample size. In the logistic analysis, PVL CSA was found to have an influence on post-procedural TPVLC-related hemolysis. Nevertheless, the wide confidence interval precludes a firm conclusion. Similarly, only non-significant differences could be identified when comparing effects of total vs. partial PVL sealing.

In conclusion, the risk of significant hemolysis associated with PVL is higher in patients with calcifications visible on fluoroscopy and mitral PVL location. Transcatheter PVL closure significantly reduces hemolysis and leads to an increase of HGB concentration and RBCC in a 6-month follow-up. These effects are dependent on the degree of achieved PVL sealing, and incomplete closure may increase the magnitude of hemolysis after TPVLC. Optimally, the technique used during implantation of the occluders should allow one to avoid any residual leakage, both beside and across the devices' structure. A small percentage of patients experience exacerbation of hemolysis after TPVLC, which usually remains clinically irrelevant. The influence of TPVLC on hemolysis is noticeable shortly after the procedure and persistent in mid-term follow-up.
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